Champions strikes deal with Concordia
Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.
Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.
As a part of the royalty agreement, Champions will use its Biomerk Tumorgraft Preclinical Platform to evaluate a combination therapy indication for the compound.
Articles in this issue
Genetics opens new window on acute myeloid leukemia
Pralatrexate: Upfront Rx strategy for T-cell lymphoma
Who's News
Functional MRI boosts early staging of cervical cancer
Unseen bone lesions flare up on post-Rx NSCLC scans
Exercise jumpstarts quality of life in lung ca
Champions strikes deal with Concordia
Oncolytics kicks off reovirus trial
PET/CT picks up additional lesions not found on chest CT
Targeted therapies address hard-to-treat liver tumors
Should ADT be part of care for all patients with intermediate-risk prostate cancer?
ASTRO hosts IT project; ASCO weighs in on stimulus plan
Calculate, negotiate: Pay heed to your non-CMS fees
Breast tissue evaluation with fine-needle aspiration fast tracks cancer Rx planning
Investing in future generationsSharon Murphy, MD, views pediatric oncology as a chance to affect an entire lifetime.
Recent Videos
Related Content
